Needham Maintains Buy on Immunocore Hldgs, Lowers Price Target to $78
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on Immunocore Holdings (NASDAQ:IMCR) but lowers the price target from $81 to $78.
September 17, 2024 | 9:53 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Gil Blum maintains a Buy rating on Immunocore Holdings but lowers the price target from $81 to $78, indicating a slight decrease in expected valuation.
The maintenance of a Buy rating suggests continued confidence in the stock's potential, but the lowered price target indicates a slight reduction in expected valuation. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100